首页> 外文期刊>BMC Complementary and Alternative Medicine >Randomized clinical trial of a phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for chronic constipation
【24h】

Randomized clinical trial of a phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for chronic constipation

机译:含有茴香皮平菇,小茴香,黑接骨草和决明子的植物治疗化合物治疗慢性便秘的随机临床试验

获取原文
           

摘要

Background A phytotherapic compound containing Pimpinella anisum L., Foeniculum vulgare Miller, Sambucus nigra L., and Cassia augustifolia is largely used in Brazil for the treatment of constipation. However, the laxative efficacy of the compound has never been tested in a randomized clinical trial. The aim of this study was to evaluate the efficacy and safety of the product. Methods This randomized, crossover, placebo-controlled, single-blinded trial included 20 patients presenting with chronic constipation according to the criteria of the American Association of Gastroenterology. The order of treatments was counterbalanced across subjects: half of the subjects received the phytotherapic compound for a 5-day period, whereas the other half received placebo for the same period. Both treatment periods were separated by a 9-day washout period followed by the reverse treatment for another 5-day period. The primary endpoint was colonic transit time (CTT), measured radiologically. Secondary endpoints included number of evacuations per day, perception of bowel function, adverse effects, and quality of life. Results Mean CTT assessed by X ray was 15.7 hours (95%CI 11.1-20.2) in the active treatment period and 42.3 hours (95%CI 33.5-51.1) during the placebo treatment (p Conclusions The findings of this randomized controlled trial allow to conclude that the phytotherapic compound assessed has laxative efficacy and is a safe alternative option for the treatment of constipation. Trial registration ClinicalTrial.gov NCT00872430
机译:背景技术在巴西,包含茴香皮氏平菇,大叶白千层,黑接骨木和奥古斯丁的植物治疗化合物在巴西广泛用于便秘的治疗。但是,该化合物的通便功效从未在随机临床试验中进行过测试。这项研究的目的是评估产品的功效和安全性。方法根据美国胃肠病学协会的标准,该随机,交叉,安慰剂对照,单盲试验包括20例患有慢性便秘的患者。各受试者的治疗顺序是平衡的:一半受试者接受了5天的植物治疗化合物,而另一半受试者接受了同期的安慰剂。两个治疗期之间相隔9天的清除期,然后再进行5天的反向治疗。主要终点是通过放射学测量的结肠转运时间(CTT)。次要终点包括每天的撤离次数,对肠功能的感知,不良反应和生活质量。结果在积极治疗期间,通过X射线评估的平均CTT为15.7小时(95%CI 11.1-20.2),在安慰剂治疗期间为42.3小时(95%CI 33.5-51.1)(p结论)该随机对照试验的结果可实现以下目标:结论认为,所评估的植物治疗化合物具有通便功效,是治疗便秘的安全替代选择临床注册ClinicalTrial.gov NCT00872430

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号